“5 Questions With…” is a weekly BioBuzz series where we reach out to interesting people in the BioHealth Capital Region to share a little about themselves, their work, and maybe something completely unrelated. March is WOMEN’S HISTORY MONTH and BioBuzz will celebrate by featuring Women in the BioHealth industry all month, especially in “5 Questions With…”. This week we continue the series with Natalie McKinney, Industry Programs Director, Biologics, US Pharmacopeia.
New buildings are now rising out of the ground on the first major phase of construction at the 235-acre, $5.5-billion, multi-decade Port Covington development. Construction on five new buildings totaling 1.1 million sq. ft. is underway with a tower crane currently on the site. The Port Covington Development Team held a groundbreaking today to celebrate the start of vertical construction.
Image: https://www.southbmore.com
ROCKVILLE, Md. and BEIJING, March 24, 2021 /PRNewswire/ — CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announced the pricing of an underwritten public offering of 15,853,658 shares of its common stock at a price to the public of $2.05 per share. CASI has granted the underwriters an option to purchase up to an additional 2,378,048 shares of common stock, which terminates on the earlier of 30 days and the day before CASI files to the U.S. Securities and Exchange Commission (“SEC”) its Annual Report on Form 10-K for the fiscal year ended December 31, 2020. The offering is expected to close on or about March 26, 2021, subject to satisfaction of customary closing conditions. The gross proceeds to CASI from the offering, excluding any exercise by the underwriters of their option to purchase additional shares, are expected to be approximately $32.5 million, before deducting underwriting discounts and commissions and other offering expenses payable by CASI.
ROCKVILLE, Md.–(BUSINESS WIRE)–NeoImmuneTech, Inc. (KOSDAQ: 950220), a clinical-stage T cell-focused biopharmaceutical company, today announced the closing of its initial public offering of 3,133,334 shares of common stock, equivalent with 15,666,670 Korea Depository Receipts (KDRs) priced at KRW 37,500 per share, equivalent with KRW 7,500 per KDRs. The aggregate gross proceeds to NeoImmuneTech, before deducting underwriting discounts and commissions and other offering expenses, were KRW 117.5 billion ($103.4 million). NeoImmuneTech’s common stock began trading on the Korea Exchange on March 16, 2021, under the KOSDAQ code number “950220.”
Our AstraZeneca Gaithersburg Campus will be illuminated this week to pay tribute to José Baselga, our beloved Oncology R&D leader and Site Head who passed away last weekend. Our entire community is devasted by this unexpected news following a period of temporary medical leave that he began in January 2021. An outstanding scientific leader, José leaves a lasting legacy in the scientific community and especially here at AstraZeneca Gaithersburg. He set our Oncology R&D function on a remarkable trajectory, and his visionary leadership, deep scientific expertise and strategic insight have delivered so many achievements that will benefit patient lives in the years to come. The blue and garnet lights were chosen to celebrate his favorite hometown soccer club, FC Barcelona. He will be deeply missed across our campus, and we will continue to be inspired by his work and vison.
For any inquiries please reach out to Joe Sanchez at joseph.sanchez @astrazeneca.com.
BrainScope received FDA clearance in September 2016 to sell its first product, which it developed with the Department of Defense to assess a range of traumatic brain injuries.
Image: Susan Hertzberg is CEO and chairwoman of Bethesda-based BrainScope. COURTESY BRAINSCOPE
When Novavax Inc. received $1.6 billion last year from the federal government to speed up testing and production of a coronavirus vaccine, some observers were incredulous. The small biotechnology firm, based in Gaithersburg, Maryland, was largely unknown and had never successfully brought a product to market.
But now that the company nears completion of its Phase 3 trials for its COVID-19 vaccine, which was found to be nearly 90% effective during clinical testing in the United Kingdom, it is grabbing headlines around the world.
Rockville, Md. — The Montgomery County Economic Development Corporation (MCEDC) awarded a total of $96,430 to six small life science companies as part of its recently completed Bio Lab Pilot Project. The project was launched in 2019 to assist local growth-stage life science companies with their wet lab and infrastructure needs. Applicants seeking financial help to build out small wet lab space less than 5,000 SF were encouraged to apply for $10 per SF of lab fit out costs, up to $30,000 per company. Project funding was provided by MCEDC and the Maryland Department of Commerce.
COLUMBIA, Md. (March 25, 2021) –TEDCO, Maryland’s economic engine for technology companies, announced today its request for applications for the Agriculture and Rural Rebuild (ARR) Challenge, created to assist Maryland’s rural and agricultural businesses that have been detrimentally impacted by the COVID-19 pandemic and associated economic downturn. TEDCO will award grants up to $200,000 per project.
“The ARR Challenge encourages purposeful collaboration between rural businesses, research institutions and industry partners,” stated Dr. Arti Santhanam, MII executive director. “Examples of a successful project may include, but is not limited to, the development of an innovative product or a novel application of an existing technology applicable to agriculture or other rural industry sectors.”
WASHINGTON, March 23, 2021 /PRNewswire/ — Congenital heart disease (CHD) affects six out of 1,000 babies born in the U.S. each year and is often complicated by arrhythmias, a condition where the heart beats too rapidly, too slowly or irregularly due to a misfiring of the body’s electrical impulses. While the last decade brought great advances in technologies that improve the care of adult arrhythmias, pediatric patients have been left behind, with only five devices approved for use in children in the same period. As a result, pediatric specialists are often using off-label or improvised devices to treat pediatric arrhythmias, including in the smallest newborns.
